Multiple Myeloma (MM) Profile, FISH

TEST: 510325
Test number copied
CPT: Contact CPT coding department at 800-222-7566, ext 6-8400.
Print Share

Synonyms

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Plasma Cell Leukemia

Test Includes

Fluorescence in situ hybridization (FISH) for multiple myeloma (MM), targeting 13q14, IGH/CCND1, TP53, FGFR1/IGH, cMAF/IGH, amplification of 1p/1q, on plasma enriched cells.

Special Instructions

Indicate pertinent clinical diagnosis and previous cytogenetics studies on the test request form. If insufficient plasma cells are available, the following probe priority will be followed: Previous abnormality, p53, FGFR3/IGH, MAF/IGH, 1p/1q, 13q14, CCND1/IGH, 7/9/15 aneuploidy probes. If a chromosome study (510999) is ordered concurrently and sample is not sufficient for both tests, FISH will be prioritized.

Expected Turnaround Time

5 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Information

Related Documents

Specimen Requirements

Specimen

Bone marrow

Volume

1 to 3 mL bone marrow

Minimum Volume

1 mL bone marrow

Container

Green-top (sodium heparin) tube with bone marrow aspirate

Collection

Transport to the testing lab at room temperature; use a cool pack or LabCorp transport kit. Do not allow sample to freeze. Sample must arrive in the laboratory within 72 hours of collection.

Storage Instructions

Maintain specimen at room temperature.

Causes for Rejection

Whole blood; broken Vacutainer®; specimen received at testing facility 72 hours after collection

Test Details

Use

This is a diagnostic test for multiple myeloma. Plasma cell enrichment diagnosis increased as much as 50% to 100%. The FISH results on the enriched assay should not be used as a quantitative assay, since the abnormal cells do not represent the percentage of abnormal cells in the aspirate.

Limitations

Molecular mutations below the resolution of FISH will not be detected. This test also will not detect regions not targeted by FISH probes.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.

Methodology

Fluorescence in situ hybridization (FISH) and plasma cell enrichment

References

Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 2004 Feb 15; 64(4):1546-1558. 14989251
Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group Molecular Classification of Multiple Myeloma: Spotlight review. Leukemia. 2009 Dec; 23(12):2210-2221. 19798094
Pozdnyakova O, Crowley-Larsen P, Zota V, et al. Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. Cancer Genet Cytogenet. 2009 Mar; 189(2):112-117. 19215792

LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf